NorthStar Medical Radioisotopes and GE Healthcare Sign Exclusive U.S. Manufacturing and Distribution Agreement
August 03 2021 - 8:00AM
Business Wire
− Collaboration will produce and distribute
Iodine-123 (I-123) capsules, the proven radiopharmaceutical
standard in diagnostic imaging studies for thyroid disease –
NorthStar Medical Radioisotopes, LLC, a global innovator in the
development, production and commercialization of
radiopharmaceuticals used for medical imaging and therapeutic
applications, and GE Healthcare today announced the signing of an
exclusive agreement for the manufacturing and distribution of
iodine-123 (I-123) capsules in the United States. Under the
contract terms, GE Healthcare’s Pharmaceutical Diagnostics unit
will manufacture and supply NorthStar with I-123 capsules under the
NorthStar label using a new, state-of-the-art production system at
its facility in Arlington Heights, Ill. Upon receipt of the
required regulatory approvals, NorthStar will retain exclusive U.S.
marketing and distribution rights for these I-123 capsules, which
will be available in 100µCi and 200µCi formulations.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210803005064/en/
Iodide I-123 (as sodium iodide I-123) is a radioisotope of
iodine, a staple product in radiopharmacies that is used routinely
in nuclear medicine as the proven standard for the diagnosis of
physiological abnormalities in the thyroid, including thyroid
cancer. The American Cancer Society estimates that approximately
44,280 Americans will be diagnosed with thyroid cancer in 2021.
“This exclusive sales and manufacturing agreement marks
NorthStar’s strong and growing relationship with GE Healthcare, and
we look forward to working with the company in meeting the needs of
radiopharmacy customers and the patients we all serve,” said
Stephen Merrick, President and Chief Executive Officer of NorthStar
Medical Radioisotopes. “NorthStar is strongly committed to the
future of nuclear medicine. The ability to provide I-123 further
expands our diagnostic imaging portfolio, which includes
domestically produced, non-uranium Mo-99/technetium-99m and
FibroScint, a novel fibrin-specific diagnostic imaging agent with
potential clinical utility in cardiovascular care.”
“We are pleased to sign this agreement and look forward to
working with NorthStar in providing patients across the United
States with I-123 capsules,” said Chris Vessell, U.S. Nuclear
Medicine Supply Chain Leader, GE Healthcare Pharmaceutical
Diagnostics. “NorthStar has proven itself a leader in successfully
driving technology development to produce innovative, real-world
solutions for radioisotope production to meet healthcare needs, and
we anticipate a productive relationship with the company.”
GE Healthcare Pharmaceutical Diagnostics imaging agents support
three patient procedures every second worldwide across MRI,
X-ray/CT, ultrasound and nuclear medicine imaging.
About GE Healthcare
GE Healthcare is the $18 billion healthcare business of GE
(NYSE: GE). As a leading global medical technology, pharmaceutical
diagnostics and digital solutions innovator, GE Healthcare enables
clinicians to make faster, more informed decisions through
intelligent devices, data analytics, applications and services,
supported by its Edison intelligence platform. With over 100 years
of healthcare industry experience and around 47,000 employees
globally, the company operates at the center of an ecosystem
working toward precision health, digitizing healthcare, helping
drive productivity and improve outcomes for patients, providers,
health systems and researchers around the world. Follow us on
Facebook, LinkedIn, Twitter, and Insights for the latest news, or
visit our website www.gehealthcare.com for more information. For
information about GE’s forward-looking statements, see
https://www.ge.com/investor-relations/important-forward-looking-statement-information
About NorthStar Medical Radioisotopes, LLC
(NorthStar)
NorthStar Medical Radioisotopes is a commercial-stage nuclear
medicine company that develops, produces and manufactures reliable
and environmentally-friendly diagnostic and therapeutic
radiopharmaceuticals. Its first FDA-approved diagnostic imaging
product is technetium-99m (Tc-99m), which is used in 40,000 patient
imaging studies per day in the United States as standard of care to
assess extent and severity of heart disease and cancer. Tc-99m is
generated by NorthStar’s novel RadioGenix® System (technetium
Tc-99m generator) which uses U.S.-produced, non-uranium based
molybdenum-99 (Mo-99) as its source material. The Company is
executing a well-defined plan to consistently increase the scale of
Mo-99 production and to continuously improve efficiencies to meet
anticipated increased demand. Therapeutic radioisotopes are
increasingly important cancer treatment options, and NorthStar is
developing commercial-scale production technologies to meet high
demand for their use in ongoing clinical trials by multiple
pharmaceutical companies. In addition, the Company is advancing a
portfolio of other radiopharmaceuticals for use in therapeutic and
diagnostic applications. For more information, visit:
www.northstarnm.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210803005064/en/
For NorthStar Medical Radioisotopes, LLC Corporate: Lisa
Holst Vice President Sales and Marketing 678-471-9027
lholst@northstarnm.com Investor Relations: Paul Estrem Executive
Vice President and Chief Financial Officer 608-987-8318
pestrem@northstarnm.com Media: Priscilla Harlan 781-799-7917
pharlan@shiningrockllc.com For GE Healthcare David Morris
Communications Director, Pharmaceutical Diagnostics GE Healthcare
+44 7920 591 370 David.j.morris@ge.com
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Aug 2024 to Sep 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Sep 2023 to Sep 2024